Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 01 Nov 2024 07:04 CET |
LYTIX BIOPHARMA AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 01 Nov 2024 07:04 CET |
LYTIX BIOPHARMA AS | Finansiell kalender | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 24 Oct 2024 14:11 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma Highlights Positive Data on LTX-315 in Collaboration with Verrica Pharmaceuticals at 2024 Fall Clinical Dermatology Conference | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 29 Aug 2024 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma Q2 and H1 2024 results: Significant clinical advancements take Lytix Biopharma closer to commercialization | 20103010 Biotechnology | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 23 Aug 2024 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Invitation to Q2 2024 Results Presentation | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 14 Aug 2024 13:37 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Foreløpige hovedresultater fra fase II-studie i pasienter med hudkrefttypen basalcellekarsinom viser 86 % total reduksjon i svulststørrelse, fullstendig fjerning av svulstene i halvparten av pasientene og potensial som førstelinjeterapi | 20103010 Biotechnology | Inside information |
| 14 Aug 2024 13:37 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: Phase II preliminary results from skin cancer (BCC) clinical trial show an 86 percent overall reduction of tumor size, complete clearance in half of the patients and the potential to be utilized as a first-line therapy | 20103010 Biotechnology | Innsideinformasjon |
| 06 Aug 2024 16:38 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: Lytix’ lisensieringspartner Verrica Pharmaceuticals publiserer foreløpige hovedresultater fra del 2 av deres fase II-studie av LTX-315 i hudkreftsykdommen basalcellekarsinom onsdag 14. august 2024 | 20103010 Biotechnology | Non-regulatory press releases |
| 06 Aug 2024 16:38 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: Lytix’s licensing partner, Verrica Pharmaceuticals, to release preliminary topline results from part 2 of their Phase II trial of LTX-315 for the treatment of the skin cancer disease basal cell carcinoma on August 14, 2024 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 30 May 2024 07:01 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones | 20103010 Biotechnology | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 22 May 2024 11:47 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Invitation to presentation of first quarter 2024 results, Thursday 30 May 2024 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 14 May 2024 14:28 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma – Minutes of Ordinary General Meeting | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 13 May 2024 15:15 CEST |
LYTIX BIOPHARMA AS | LYTIX BIOPHARMA AS - NEW SHARE CAPITAL REGISTERED | 20103010 Biotechnology | Kapital- og stemmerettsendringer |
| 03 May 2024 16:34 CEST |
LYTIX BIOPHARMA AS | Correction in the notice of Annual General Meeting in Lytix Biopharma AS | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 30 Apr 2024 07:05 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: Notice of Annual General Meeting on 14 May 2024 | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 30 Apr 2024 07:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: Annual Report for 2023 | 20103010 Biotechnology | Årsrapporter og revisjonsberetninger |
| 26 Apr 2024 16:05 CEST |
LYTIX BIOPHARMA AS | LYTIX BIOPHARMA AS – MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDERS AND CLOSE ASSOCIATES | 20103010 Biotechnology | Meldepliktig handel for primærinnsidere |
| 26 Apr 2024 15:48 CEST |
LYTIX BIOPHARMA AS | LYTIX BIOPHARMA AS – SHARE ISSUE PURSUANT TO BOARD AUTHORIZATION | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 25 Apr 2024 17:13 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates | 20103010 Biotechnology | Meldepliktig handel for primærinnsidere |
| 25 Apr 2024 16:17 CEST |
LYTIX BIOPHARMA AS | LYTIX BIOPHARMA AS – MINUTES OF EXTRAORDINARY GENERAL MEETING AND FINAL RESULTS OF SHARE OFFERING | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 25 Apr 2024 13:46 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity. | 20103010 Biotechnology | Non-regulatory press releases |
| 25 Apr 2024 13:46 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma annonserer godkjennelse av fase II-studie i pasienter med tidligfase føflekkreft (melanom) - en betydelig kommersiell mulighet | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 24 Apr 2024 21:54 CEST |
LYTIX BIOPHARMA AS | LYTIX BIOPHARMA AS – PRELIMINARY RESULTS IN THE SHARE OFFERING | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 24 Apr 2024 07:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS - Last day of the Application Period | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 12 Apr 2024 07:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS – Ex Date | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 10 Apr 2024 23:48 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: Tilbud om tegning av aksjer, publisering av prospekt og innkalling til ekstraordinær generalforsamling | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 10 Apr 2024 14:20 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS – Notice of extraordinary general meeting 25 April 2024 | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 10 Apr 2024 12:47 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS – Publication of Prospectus and commencement of Application Period | 20103010 Biotechnology | Prospekt / opptaksdokument |
| 09 Apr 2024 18:12 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS - Key information relating to the share offer | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 09 Apr 2024 17:45 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma raising up to NOK 55 million with strong support from existing shareholders – several key milestones coming up with large commercial potential | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 09 Apr 2024 17:10 CEST |
LYTIX BIOPHARMA AS | LYTIX BIOPHARMA AS: Contemplated Offering | 20103010 Biotechnology | Innsideinformasjon |
| 02 Apr 2024 12:54 CEST |
LYTIX BIOPHARMA AS | Lytix`s approach to raise response rates to immunotherapy highlighted in the international publication MedNous | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 21 Mar 2024 12:43 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma announces the publication of a paper describing how LTX-315 mediates antitumor activity through multiple pathways | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 20 Mar 2024 14:54 CET |
LYTIX BIOPHARMA AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 29 Feb 2024 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma Q4 and H2 2023 results: Promising interim results from multiple phase II studies, expanding clinical roadmap to early-stage cancer patients | 20103010 Biotechnology | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 22 Feb 2024 10:36 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma: Invitation to presentation of fourth quarter and second half 2023 results, Thursday 29 February 2024 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 26 Jan 2024 12:42 CET |
LYTIX BIOPHARMA AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 23 Jan 2024 10:39 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma presenting at Redeye Fight Cancer Event 2024 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 05 Jan 2024 15:18 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma’s licensing partner Verrica Pharmaceuticals Inc. Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 29 Dec 2023 17:58 CET |
LYTIX BIOPHARMA AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 11 Dec 2023 13:14 CET |
LYTIX BIOPHARMA | Encouraging results from ATLAS-IT-04 study published in OncoImmunology | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 09 Nov 2023 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma presents third quarter 2023 results | 20103010 Biotechnology | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 08 Nov 2023 12:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma presenting at major investor conferences in London and Stockholm in November | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 02 Nov 2023 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma: Presentation of third quarter 2023 results, November 9 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 25 Oct 2023 13:23 CEST |
LYTIX BIOPHARMA AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 23 Oct 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Encouraging preliminary data from Lytix Biopharma’s ATLAS-IT-05 study presented at ESMO 2023 | 20103010 Biotechnology | Innsideinformasjon |
| 20 Oct 2023 09:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma to host webcast after release of preliminary data from ATLAS-IT-05 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 17 Oct 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma granted up to NOK14.3m (US$1.3m) of public non-dilutive funding from ’SkatteFUNN’ | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 16 Oct 2023 08:51 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma’s abstract with preliminary interim Phase II data from the ATLAS-IT-05 study is published | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 09 Oct 2023 15:00 CEST |
LYTIX BIOPHARMA AS | Neoadjuvant study with LTX-315 in early-stage melanoma patients to be presented at the 15th Nordic melanoma meeting | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |